 Our goal was not to develop a pharmaceutical company but just to come up with something practical and safe and effective, explains Dr Yutaka Niihara, as he talks about how he and colleague Willis Lee formed Emmaus Life Sciences Inc OTCQX:EMMA and developed Endari L-glutamine, a treatment for the debilitating sickle cell disease. Fortunately, we found something based on our basic science research, added Niihara, who is chairman and CEO of Emmaus alongside Lee, the companys president and chief operating officer. 